Abstract: The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)-mediated diseases and diseases mediated through the activation of the Nrf2-ARE (antioxidant response element) pathway, including proliferative diseases and disorders, Alzheimer's disease, stroke, and certain diseases and disorders of aging and associated with aging and exposure, by use of the extracts, compounds, and compositions thereof.

Abstract: Disclosed herein is a composition comprising a biologically active agent; a base oil; an additional oil that is soluble in the base oil with a partition coefficient for the biologically active molecule that is at least twice that of the base oil; where the base oil and the additional oil are present in the composition in an amount effective to reduce the amount of the biologically active agent in an aqueous phase to less than 80 wt % of the amount with just the base oil present in an otherwise identical composition at the same total oil loading; a non-ionic surfactant; and water.

Abstract: Described herein are various embodiments of a valve that may be opened and closed using a thixotropic or “stress yield” material, or other material that temporarily changes phase upon application of energy to the material. More particularly, some embodiments may include a valve that is opened and closed using a granular gel that is a temporary phase change material.

Abstract: Described herein are injectable composite inks composed of a hydrogel continuous phase with a plurality of microgels present within the hydrogel continuous phase. The inks described herein have unique chemical and physical properties that enable them to be printed into a number of different types of articles. The articles produced by the injectable composite inks have numerous medical applications.

Abstract: The disclosure provides methods of treating obesity, reducing weight, or preventing weight gain using a combination therapy of GDF15 polypeptide and a myostatin inhibitor (e.g., a myostatin propeptide).

Abstract: The present disclosure relates to compositions and methods for treatment of degenerative conditions of large weight-bearing joints, such as osteoarthritis, by intra-articular delivery of a codon-modified IL-1Ra encoding gene.

Abstract: Provided are compositions and methods of treating cell proliferative disorders, especially cancer. Also provided are methods for assessing and monitoring cell proliferative processes and processes for amelioration of cell proliferative disorders, especially cancer.

Abstract: Various embodiments of the present disclosure provide a scan-based architecture for register-transfer-level (RTL) or gate-level designs that improves the security of scan chain-based design-for-testability (DFT) structures. In various embodiments, the scan-based architecture includes invisible scan chains that are hidden in such a way that an attacker cannot easily identify or locate the invisible scan chains for exploitation and revealing internal secure information of the design. The invisible scan chains are dynamically configurable into a scan chain with select flip-flops, such that scan paths of the invisible scan chains may be different between different designs, chips, or testing operations. Various embodiments further employ key-based obfuscation by combining a scan control finite state machine with existing state machines within a design, which improves design security against unauthorized use and increases confidentiality.

Abstract: The present disclosure describes systems, apparatuses, and methods for obfuscation-based intellectual property (IP) watermark labeling. One such method comprises identifying, by one or more computing processors, a specific net within an integrated circuit design that is likely to be used in a malicious attack; and adding additional nets to the integrated circuit design that add additional logic states to a finite state machine present in the integrated circuit design. The additional logic states comprise watermarking states for performing authentication of the integrated circuit design, in which a watermark digest can be captured upon application of secret key inputs to the additional nets. Other methods, systems, and apparatuses are also presented.

Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.

Abstract: The disclosure relates to macrocyclic peptides and pharmaceutical compositions thereof. The disclosure further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.

Abstract: Various examples are provided for accurate heart rate measurement. In one example, a method includes determining a respiratory rate (RR) and respiration displacement from radar-measured cardiorespiratory motion data; adjusting notch depths of a harmonics comb notch digital filter (HCNDF) based upon the respiration displacement; generating filtered cardiorespiratory data by filtering the radar-measured cardiorespiratory motion data with the HCNDF; and identifying a heart rate (HR) from the filtered cardiorespiratory data. In another example, a system includes radar circuitry configured to receive a cardiorespiratory motion signal reflected from a monitored subject; and signal processing circuitry configured to determine a respiration displacement based upon the cardiorespiratory motion signal; adjust notch depths of a HCNDF based upon the respiration displacement; filter the cardiorespiratory motion data with the HCNDF; and identifying a heart rate (HR) from the filtered cardiorespiratory data.

Abstract: The present disclosure describes various embodiments of systems, apparatuses, and methods for implementing an array antenna having a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers. One such antenna device comprises an array of patch antennas on a substrate, wherein the patch antennas are formed of a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers; and a microstrip feeding line coupled to the array of patch antennas. Other systems, apparatuses, and methods are also presented.

Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.

Abstract: Disclosed are various embodiments of memristive devices comprising a number of nodes. Memristive fibers are used to form conductive and memristive paths in the devices. Each memristive fiber may couple one or more nodes to one or more other nodes. In one case, a memristive device includes a first node, a second node, and a memristive fiber. The memristive fiber includes a conductive core and a memristive shell surrounding at least a portion of the conductive core along at least a portion of the memristive fiber. The memristive fiber couples the first node to the second node through a portion of the memristive shell and at least a portion of the conductive core.

Abstract: Provided herein are modified insecticidal proteins comprising an insecticidal protein, wherein the insecticidal protein has been modified to include at least one stink bug gut binding peptide.

Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.

Abstract: Provided herein are genetically engineered cells containing one or more modulated metabolic genes, where the expression of the modulated metabolic gene(s) can be greater than that of an unmodified control. Also provided herein are methods of making the genetically engineered cells using synergistic activation mediator CRISPR-Cas9. Further provided herein are high throughput assays that can employ the genetically engineered cells provided herein.